– PDE9 inhibitor, CRD-740, demonstrated favorable safety profile and achieved statistical significance for the trial’s primary endpoint, median increase in plasma cyclic guanosine monophosphate (cGMP) – – This clinical trial confirms that high levels of PDE9 inhibition lead to increases in cGMP, reflecting increased activation of the myocardial natriuretic peptide (NP) signaling pathway – – … [Read more…]

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759 restricted stock units (RSUs) of the company’s common stock to 14 … [Read more…]

Engineering of X-Editors (XE), Scribe’s proprietary genome editing platform, for potency and specificity enables XE to become the first non-Cas9-based molecule to achieve saturating levels of editing in the NHP liver (exceeding 75% whole liver editing) without any detectable off-targets Data also highlight the ability of XE to achieve safe and saturated levels of editing … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “PEGylated Proteins Market 2023-2028” report has been added to ResearchAndMarkets.com’s offering. The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and is projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 … [Read more…]

New Cardiovascular Age and Cardio Capacity capabilities further establish ŌURA as a personal health companion for improving healthspan and longevity SAN FRANCISCO–(BUSINESS WIRE)–ŌURA, maker of Oura Ring, the most accurate and trusted smart ring, announced the launch of two new heart health features: Cardiovascular Age (CVA) and Cardio Capacity. The two product advancements signal the … [Read more…]

This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CastleBiosciences–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the “Best Overall Mental Health Solution” … [Read more…]

LONDON–(BUSINESS WIRE)–Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to more effectively target chemotherapy treatment for women who have hormone receptor-positive (HR+), human epidermal growth factor … [Read more…]

BRENTWOOD, Tenn.–(BUSINESS WIRE)–Lifepoint Health, Inc. (the “Company”) today announced that it has priced its offering of $800 million aggregate principal amount of 10.000% Senior Notes due 2032 (the “Notes”) at an issue price of 100.000% in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the … [Read more…]

Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion NOVA LIMA, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three-month period ended March 31, 2024 (first quarter 2024). Financial results … [Read more…]

NEW YORK–(BUSINESS WIRE)–$MNMD–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences: 2024 RBCCM Global Healthcare Conference Format: Fireside Chat Date and Time: Wednesday, May … [Read more…]